Imatinib (Gleevec)-induced hepatotoxicity.

@article{Ayoub2005ImatinibH,
  title={Imatinib (Gleevec)-induced hepatotoxicity.},
  author={Walid S. Ayoub and Stephen A. Geller and Tram Tran and Paloma Porras Mart{\'i}n and John Moore Vierling and Fred F Poordad},
  journal={Journal of clinical gastroenterology},
  year={2005},
  volume={39 1},
  pages={
          75-7
        }
}
Imatinib (Gleevec, Novartis Pharmaceuticals Corp, East Hanover, NJ) is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. To our knowledge, only one case report of histologically proven Imatinib-induced hepatotoxicity has been reported. We describe another case of hepatotoxicity in a 22-year-old woman including the histopathologic changes and the clinical course after the discontinuation of Imatinib. 

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

Imatinib-induced subclinical liver injury: histological changes of non-tumorous hepatic parenchyma

Boonchoo Sirichindakul, Virote Sriuranpong, +3 authors Supanit Nivatvongs
  • 2011
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

A Case of Imatinib-Induced Hepatitis

VIEW 1 EXCERPT
CITES BACKGROUND

Similar Papers